Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | GALR1 | P47211 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5146537 | 0.98 | KIF11 (0.48) | KIF11PTGS2PTGS1MAOBTNKS | |
| SCHEMBL5146697 | 0.95 | KIF11 (0.50) | KIF11PTGS2PTGS1MAOBTNKS | |
| SCHEMBL1847395 | 0.90 | KIF11 (0.54) | KIF11PTGS2PTGS1MAOBALDH1A1 | |
| SCHEMBL5146558 | 0.76 | KIF11 (0.46) | KIF11ALDH1A1KDM4ENISCHTSHR | |
| SCHEMBL13410633 | 0.76 | KIF11 (0.78) | KIF11MAOBALDH1A1TSHR | |
| SCHEMBL29914837 | 0.76 | KIF11 (0.78) | KIF11MAOBALDH1A1TSHR | |
| SCHEMBL197238 | 0.76 | KIF11 (0.78) | KIF11MAOBALDH1A1TSHR | |
| SCHEMBL4329010 | 0.74 | SLC6A2 (0.47) | KIF11KDM4ENISCHTSHR | |
| SCHEMBL8355638 | 0.73 | ASIC3 (0.46) | KIF11NISCH | |
| SCHEMBL14894144 | 0.73 | WNT3A (0.47) | KIF11PTGS2PTGS1TNKSWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104918942-A | Pyrimidone derivatives and their use for treating, ameliorating or preventing viral diseases | SAVIRA PHARMACEUTICALS GMBH | 2015-09-16 | — | — | CN | disclosed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNA5, KCNH1, KCNK5 | KIF11 862/4885PTGS2 3165/4885PTGS1 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.